Cibus, Inc.

NASDAQ:CBUS

Biotechnology

Healthcare
$1.37 +3.10%

+$0.04 today

Market cap
$104.71M
Beta
1.65
P/E (TTM)
-8.6
EPS (TTM)
-$0.16
52W Low $1.09High $4.19

Volume 0.25M

Average 0.51M

CBUS Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Cibus, Inc.NASDAQ: CBUS

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $8.72M fell 26.1% year over year, behind the -18.1% change in trailing-twelve-month research & development. Sequentially, it fell 7.1% from the prior quarter. Over 3 fiscal years it compounded at +56.4% a year.

Context

  • Research & development amounted to 1214.6% of revenue in FY2025, up 31.3 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -26.1% toward the trailing-twelve-month pace of -18.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$8.72M-7.1% QoQ
Last fiscal yearDec 2025
$44.2M-12.4% YoY
LTMMar 2026
$41.12M-18.1% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-26.1%——
1 year-12.4%——
3-year CAGR+56.4%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
44.2M USD
Year-over-year change
-12.4%
4-year CAGR
+40.5%

Research & Development vs competitors

How CBUS compares with its peers on the latest reported figures

  • CBUS's LTM Mar 2026 research & development of $41.12M is the 7th highest of the 10 companies compared; the peer median is $59.66M.
  • Its year-over-year change of -18.1% is the 7th highest of 10, against a peer median of -3.9%.
  • Research & development amounts to 959.3% of revenue for CBUS, versus a peer median of 958.2%.
CBUS Competitors Peer median
Research & Development for CBUS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MNOVMediciNova, Inc.LTM Mar 2026$1.27B +18127.2%-7.8%212494.0%
VXRTVaxart, Inc.LTM Mar 2026$200.25M +133.0%+35.5%78.3%
IMUXImmunic, Inc.LTM Mar 2026$86.08M +3.9%+4.8%—
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$67.7M +8.5%+10.6%—
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$59.66M -11.8%+35.8%—
BMEABiomea Fusion, Inc.LTM Mar 2026$48.2M -55.0%-0.4%—
CBUSCibus, Inc.LTM Mar 2026$41.12M -18.1%+56.4%959.3%
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026$37.7M -3.9%—958.2%
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$23.02M -48.6%-81.3%—
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$8.57M -44.2%-9.8%—
Peer median (excluding CBUS) $59.66M-3.9%+2.2%958.2%

Competitors are the stored peer set for CBUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue25.99M157K1.82M4.26M3.64M
Cost of Revenue28.56M1.53M395K05.92M
Gross Profit(2.57M)(1.38M)1.42M4.26M(2.28M)
Gross Margin-9.9%-877.1%78.3%100.0%-62.8%
Research & Development11.34M11.55M42.37M50.43M44.2M
Selling, General & Admin15.38M9.44M28.91M30.8M26.91M
Operating Expenses26.76M20.99M320.31M262.66M65.18M
Depreciation & Amortization2.34M1.53M4.69M6.86M5.92M
EBITDA(25.43M)(15.21M)(314.59M)(241.64M)(90.77M)
EBITDA Margin-97.9%-9687.9%-17313.4%-5669.5%-2494.3%
Operating Income(29.33M)(22.37M)(318.88M)(258.4M)(67.46M)
Operating Margin-112.9%-14248.4%-17550.0%-6062.8%-1853.9%
Interest Income17K60K527K631K438K
Interest Expense1.43M87K18.89M34.19M35.48M
Other Income / Expenses133K5.48M(18.76M)(24.29M)(64.71M)
Income Before Tax(29.2M)(16.89M)(337.64M)(282.68M)(132.17M)
Pre-Tax Margin-112.4%-10758.6%-18582.4%-6632.7%-3632.1%
Income Tax Expense00(4K)29K29K
Net Income(29.2M)(16.89M)(267.63M)(251.39M)(127.09M)
Net Margin-112.4%-10758.6%-14729.1%-5898.4%-3492.3%
EPS (Basic)(0.05)(0.03)(25.95)(10.83)(2.78)
EPS (Diluted)(0.05)(0.03)(25.95)(10.83)(2.78)
Weighted Avg Shares578.47M578.47M10.31M23.22M457.57M
Weighted Avg Shares (Diluted)578.47M578.47M10.31M23.22M457.57M

Cibus, Inc.

NASDAQ:CBUS

Intrinsic Alpha fair value

Locked

Current Price

$1.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.